In the New York Stock Market, the leading index showed mixed trend while monitoring the spread of the new coronavirus infection (Corona 19) strain.
On the 22nd (hereafter Eastern time), the Dow Jones 30 Industrial Average on the New York Stock Exchange (NYSE) closed at 30,015.51, down 200.94 points (0.67%) from the battlefield.
The Standard & Poor’s (S&P) 500 index closed at 3,687.26, down 7.66 points (0.21%) from the battlefield, but the Nasdaq index, which was centered on technology stocks, rose 65.40 points (0.51%) to 12,807.92.
The S&P 500 index fell for three consecutive trading days, but the Nasdaq broke record highs in terms of intraday and closing prices.
The market watched the spread of Corona 19, the effect of introducing US stimulus measures, and major economic indicators.
Concerns over the pandemic crisis grew again as the virus strain of Corona 19 spread rapidly in the UK.
This mutation is known to be much more contagious than the existing virus.
A number of countries are taking urgent measures, such as restricting the entry of travelers from the UK.
As it is highly contagious, concerns are raised that the further spread of the variant virus will be inevitable even with restrictions on movement.
However, the anxiety is somewhat limited as the general opinion of experts that the developed Corona 19 vaccine will also be effective against a variant virus.
Anthony Pouch, the director of the National Institute of Health (NIH) Allergy and Infectious Diseases Research Institute (NIAID), argued that the vaccine would also protect against strains.
The fact that the US Congress passed a new stimulus plan worth about $900 billion the day before is a factor that provides relief.
The US administration is planning to quickly implement stimulus measures such as cash payments to citizens.
Expectations are emerging that the vaccine will be able to support the economy until it becomes more widely available.
It is unclear whether the vaccine will provide a steady boost to the year-end stock market.
This is because the two good news of the vaccine release and the introduction of US stimulus measures have already been significantly reflected in the market.
The sluggish consumption indicators released on this day hindered investment sentiment.
The conference board announced that the December consumer confidence index fell to 88.6 from 92.9 of the previous month.
It fell far short of the 97.5 market forecast compiled by the Wall Street Journal.
In addition to retail sales in November, which was released last week, indicators that provoke concerns about the recent US consumption situation are steadily coming out.
Consumption is the core support of the US economy.
By stock on that day, Tesla’s share price fell by about 1.5%, falling for two days in a row after incorporation into the S&P500 index.
The news that Apple plans to enter the autonomous electric vehicle market also had a negative impact.
Apple’s share price rose more than 2.8%.
By industry, technology stocks rose 0.86%, while industrial stocks fell 0.54%.
Energy fell 1.74%.
Other economic indicators released that day were mixed.
The U.S. Department of Commerce announced that the final 3Q gross domestic product (GDP) growth rate (seasonally adjusted value) was calculated at an annual rate of 33.4%.
This is an improvement over the previously announced 33.1% increase in the tentative value.
Market expectations were also exceeded.
The Richmond Federal Reserve announced that the manufacturing index for November rose to 19 from 15 last month.
On the other hand, the National Real Estate Brokers Association (NAR) announced that in November, the existing home sales (seasonal adjustment value) decreased 2.5% from the previous month to 6.69 million units.
It declined for the first time in the last six months.
The market forecast declined 2.2% to 6.7 million units.
New York stock market experts expressed concern over the trend of the COVID-19 mutation.
“It’s a brave person to see that the issue of variation will be limited to the UK,” said Derek Halpenny, head of global market research at MUFG Europe.
“The key is how much the new mutation will reduce the effectiveness of the vaccine,” said Peter Garney, head of equity strategy at Saxobank. Diagnosed.
On the Chicago Options Exchange (CBOE), the volatility index (VIX) recorded 24.23, down 3.7% from the previous trading day.
/yunhap news
–
